(Reuters)—UnitedHealth Group Inc, the largest U.S. health insurer, on Tuesday raised the possibility of stronger profit growth in 2017 as it exits the government-subsidized insurance market commonly known as Obamacare, encouraging investors who have been negative on the sector. The company said losses in that business were within expectations in the third quarter, news that…
Articles by Cindy Devone-Pacheco
Unclear If Sports Raise Later Arthritis Risk
(Reuters Health)—Playing team sports, especially soccer, at the elite level may lead to a higher risk for osteoarthritis, but the existing research is of such low quality it’s hard to say for sure, according to a recent review. In an analysis of past studies filled with conflicting results, researchers found that long-distance running was the…
Roche Gets Boost from FDA in Bid to Expand Uses for Actemra
ZURICH (Reuters)—The U.S. Food and Drug Administration has granted breakthrough status to Roche’s rheumatoid arthritis medication Actemra (tocilizumab) for giant cell arteritis, the Swiss drugmaker said, a step which could help it broaden applications for the medicine. Giant cell arteritis is a chronic, potentially life-threatening autoimmune condition caused by inflammation of large and medium-sized arteries,…
Express Scripts Tries to Rein in Pricey Inflammatory Drugs
NEW YORK (Reuters)—Express Scripts Holding, the largest manager of U.S. drug benefits, on Thursday launched a program aimed at tightening spending on drugs for pricey inflammatory conditions such as rheumatoid arthritis. It is the latest Express Scripts effort intended to reduce spending on prescription drugs, such as last week’s announcement of a diabetes program. Early…
Hours Spent Record Keeping May Fuel Physician Burnout
(Reuters Health)—For every hour doctors spend treating patients during a typical workday, they devote nearly two more hours to maintaining electronic health records (EHR) and clerical work, a small U.S. study suggests. Time spent in meaningful interactions with patients is a powerful driver of physician career satisfaction, but increased paperwork and time on the computer…
What Do Patients Know about Biosimilar Drugs?
(Reuters Health)—Many patients haven’t heard of biosimilars, generic versions of complex biotech drugs, and even some who say they’re familiar with these medicines may still be confused about them, a small European survey suggests.1 To see what patients know about biosimilars, researchers analyzed data from online surveys completed by 1,181 patients with irritable bowel disease…
Novartis Bid to Sell New Biosimilar Crimped by U.S. Court Battles
ZURICH (Reuters)—Novartis has won U.S. approval for a copy of Amgen’s blockbuster arthritis drug Enbrel, but the Swiss drugmaker’s bid to muscle in on the medicine’s $4.7 billion in annual U.S. revenue remains blocked by court battles. Novartis’s Sandoz unit said on Tuesday the U.S. Food and Drug Administration (FDA) approved Erelzi, its biosimilar copy…
The ACR Opposes Part B Payment Demo & Other Highlights from the AMA HOD Meeting
On June 15, the ACR and partnering physician specialist groups passed an American Medical Association (AMA) resolution opposing the proposed Medicare Part B drug payment demonstration during the AMA House of Delegates (HOD) meeting held June 11–15 in Chicago. Part B Payment Demo Resolution The resolution, which the ACR supported with the American Society of…
- « Previous Page
- 1
- …
- 26
- 27
- 28